Market Place
Sourcing Support
Dragonfly Presents Preclinical Data on DF6215 & DF9001 at SITC
07 Nov 2024 //
PR NEWSWIRE
Dragonfly Therapeutics Presents DF6215 Preclinical Data at SITC
07 Nov 2024 //
PR NEWSWIRE
Dragonfly Therapeutics Appoints Dr. Susan Altschuller as Chief Financial Officer
05 Aug 2024 //
PR NEWSWIRE
Dragonfly, Merck Collaborate On DF9001 TriNKET Plus KEYTRUDA
21 May 2024 //
PR NEWSWIRE
Dragonfly, Merck Partner to Evaluate DF9001 in Combination with Keytruda
21 May 2024 //
CONTRACT PHARMA
Dragonfly has Received Payment Following Dosing of Patient in DF4101/ABBV-303
05 Mar 2024 //
PR NEWSWIRE
Dragonfly Announces Collaboration Exploring Combinations of DF1001 with Trodelvy
15 Feb 2024 //
PR NEWSWIRE
Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy
05 Dec 2023 //
PR NEWSWIRE
Dragonfly Announces the Presentation of Phase 1 DF1001 TriNKET Results at ASCO
05 Jun 2023 //
PR NEWSWIRE
Dragonfly Therapeutics Expands Clinical Leadership Team
02 Jun 2023 //
CONTRACT PHARMA
Dragonfly to Present Phase 1 DF1001 Monotherapy Dose Escalation Results
02 Jun 2023 //
PR NEWSWIRE
Dragonfly Therapeutics Announces the Publication of Preclinical Data DF6002
17 Apr 2023 //
PR NEWSWIRE
BMS returns $475M IL-12 oncology asset to Dragonfly`s pond
07 Feb 2023 //
FIERCE BIOTECH
Dragonfly Appoints Joseph Eid as President of Research & Development
02 Feb 2023 //
CONTRACT PHARMA
Dr. Joseph E. Eid joins Dragonfly Therapeutics as President of R&D
01 Feb 2023 //
PR NEWSWIRE
BMS, Dragonfly Enter Exclusive License for Sixth TriNKET Immunotherapy Candidate
06 Jan 2023 //
CONTRACT PHARMA
Dragonfly Announces First Patient Dosed in PI Study of EGFR-targeting TriNKET
08 Dec 2022 //
PRNEWSWIRE
Dragonfly Therapeutics Initiates Phase 2 Study of HER2 Targeting TriNKET DF1001
06 Dec 2022 //
PRNEWSWIRE
Nona Biosciences Enters Agreement with Dragonfly Therapeutics
21 Nov 2022 //
PRNEWSWIRE
Dragonfly Announces First Patient Dosed in Trial Evaluating Solid Tumor TriNKET®
01 Nov 2022 //
PRNEWSWIRE
Gilead joins Big Pharma peers at Dragonfly`s pond in $300M deal
02 May 2022 //
FIERCEBIOTECH
Dragonfly Therapeutics Expands Research Collaboration with Abbvie
20 Apr 2022 //
CONTRACTPHARMA
Merck extends pact with Artiva; Regeneron-allied biotech pencils in $15M IPO
11 Apr 2022 //
ENDPTS
Dragonfly Tx Achieves Phase 1 Development Milestone for IL-12 Program with BMS
01 Mar 2022 //
PRNEWSWIRE
Dragonfly gets Merck on second TriNKET candidate since 2018 collab; & more
23 Nov 2021 //
ENDPTS
Dragonfly Announces Sixth Dragonfly Drug to be Licensed Bristol Myers
18 Oct 2021 //
PRNEWSWIRE
Dragonfly Biosciences Launches Global Outreach Into Australia
21 Apr 2021 //
PRNEWSWIRE
Merck’s Roger Perlmutter buys his first solid tumor TriNKET from Dragonfly
02 Dec 2020 //
ENDPTS
Merck opts in for Dragonfly`s TriNKET cancer program
02 Dec 2020 //
FIERCE BIOTECH
BMS agrees to acquire biotherapeutics developer Forbius
25 Aug 2020 //
PHARMACEUTICALTECHNOLOGY
Aiming for immunotherapy boost, Bristol Myers deepens ties with Dragonfly
18 Aug 2020 //
BIOPHARMADIVE
Aiming for immunotherapy boost, Bristol Myers deepens ties with Dragonfly
17 Aug 2020 //
PHARMADIVE
Dragonfly Therapeutics Announces BMS Opt-In Fourth TriNKET™ Immunotherapy Drug
09 Aug 2020 //
PRNEWSWIRE
Dragonfly Therapeutics Initiates Ph 1/2 Study of its IL12 Immunotherapy
21 Jul 2020 //
PRNEWSWIRE
A booming Dragonfly is taking its TriNKETs to Copenhagen as the Bristol Myers
06 Jul 2020 //
ENDPTS
Dragonfly Announces New Research Collaboration with Bristol Myers Squibb
06 Jul 2020 //
PRNEWSWIRE
Dragonfly Therapeutics Announce Multi-Target Expansion of its Collab with Merck
19 Mar 2020 //
PRNEWSWIRE
